Mesothelioma Related Clinical Trials:
Preoperative Chemotherapy Of Potentially Resectable Mesothelioma Of The Pleura

Article Tools:

In Page Navigation: - General Info - Purpose - Eligibility - Contacts & Locations - Additional Information

   

Status: Active
Sponsors and Collaborators: Swiss Group for Clinical Cancer Research
Information provided by: National Cancer Institute (NCI)
Government Identifier: NCT00030745

Condition: Malignant Mesothelioma
Intervention: Drug: cisplatin; Drug: gemcitabine hydrochloride; Procedure: chemotherapy; Procedure: conventional surgery

    - Return To Top

Purpose:


RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs before surgery may shrink the tumor so that it can be removed during surgery.

PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have mesothelioma of the lung.

Study Type:   Interventional
Study Design:   Treatment
Official Title:   Preoperative Chemotherapy Of Potentially Resectable Mesothelioma Of The Pleura

Further study details as provided by National Cancer Institute (NCI):

Study Start Date:   June 2000

Detailed Description:

OBJECTIVES:

  • Determine the proportion of patients with potentially resectable mesothelioma of the pleura remaining operable after treatment with neoadjuvant cisplatin and gemcitabine.
  • Determine the response rate and overall survival of patients treated with this regimen.
  • Determine the tolerability of this regimen in these patients.
  • Determine the number of postoperative hospitalization days and occurrence and duration of surgical complications in patients treated with this regimen.
  • Determine the quality of life of patients treated with this regimen.
  • Compare the proportion of patients who report psychological distress at 3 months after surgery vs at study registration.

OUTLINE: Patients receive cisplatin IV on day 1 and gemcitabine IV on days 1, 8, and 15. Treatment repeats every 28 days for 3 courses. Within 6 weeks after completion of chemotherapy, patients undergo restaging by CT scan followed by surgical resection.

Quality of life is assessed at baseline, day 1 of course 3, within 4 weeks after surgery, and then at 3 and 6 months.

Patients are followed every 3 months for 1 year and then every 6 months thereafter.

PROJECTED ACCRUAL: A total of 61 patients will be accrued for this study.

    - Return To Top

Eligibility:

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

DISEASE CHARACTERISTICS:

  • Histologically and clinically confirmed pleural mesothelioma
    • Stages T1-3, N0-2, M0 by CT scan of the chest
      • Mediastinoscopy required for staging of mediastinal lymph nodes
    • Considered completely resectable

PATIENT CHARACTERISTICS:

Age:

  • Over 18

Performance status:

  • WHO 0-2

Life expectancy:

  • Not specified

Hematopoietic:

  • Not specified

Hepatic:

  • No severe liver disease

Renal:

  • Creatinine no greater than 1.7 mg/dL

Cardiac:

  • Adequate cardiac function
  • No cardiac disease that would preclude forced hydration or surgery

Pulmonary:

  • Predicted postoperative FEV_1 greater than 1 by spirometry

Other:

  • No contraindication to surgery
  • No other prior or concurrent malignancy except adequately treated carcinoma in situ of the cervix or basal cell or squamous cell skin cancer
  • No uncontrolled infection
  • No uncontrolled diabetes
  • No neurologic or psychiatric disorders that would preclude study compliance
  • No other serious illnesses that would preclude study participation
  • No other circumstances that would preclude study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Not specified

Chemotherapy

  • Not specified

Endocrine therapy

  • Not specified

Radiotherapy

  • Not specified

Surgery

  • No prior pleurectomy or lung resection except for diagnostic purposes

    - Return To Top

Contacts and Locations:

Please refer to this study by its ClinicalTrials.gov identifier: NCT00030745
Locations
Switzerland
UniversitaetsSpital    
      Zurich, Switzerland, CH-8091

Sponsors and Collaborators
Swiss Group for Clinical Cancer Research

Investigators
Study Chair:     Rolf A. Stahel, MD     UniversitaetsSpital Zuerich    

    - Return To Top

Additional Information:

Study ID Numbers:   CDR0000069194, SWS-SAKK-17/00, EU-20136
First Received:   February 14, 2002
Last Updated:   November 16, 2007
ClinicalTrials.gov Identifier:   NCT00030745
Health Authority:   United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
localized malignant mesothelioma  

Study placed in the following topic categories:
Cisplatin
Mesothelioma
Gemcitabine
Adenoma
Neoplasms, Glandular and Epithelial

Additional relevant MeSH terms:
Mesothelioma
Antimetabolites
Anti-Infective Agents
Neoplasms by Histologic Type
Antimetabolites, Antineoplastic
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Neoplasms, Mesothelial
Antineoplastic Agents
Physiological Effects of Drugs
Enzyme Inhibitors
Immunosuppressive Agents
Antiviral Agents
Pharmacologic Actions
Neoplasms
Radiation-Sensitizing Agents
Therapeutic Uses

    - Return To Top

Free case consultation

If you or a loved one has been diagnosed with mesothelioma or another asbestos-related disease, contact us using the form below to speak with a mesothelioma consultant, free of charge.